Louise Chen
Stock Analyst at Scotiabank
(3.30)
# 1,007
Out of 5,127 analysts
297
Total ratings
47.33%
Success rate
2.64%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Sector Outperform | $35 → $40 | $34.47 | +16.04% | 5 | Jan 29, 2026 | |
| JNJ Johnson & Johnson | Maintains: Sector Outperform | $230 → $265 | $238.64 | +11.05% | 41 | Jan 22, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Sector Perform | $53 → $60 | $60.77 | -1.27% | 2 | Jan 9, 2026 | |
| MRK Merck & Co. | Maintains: Sector Outperform | $105 → $120 | $117.65 | +2.00% | 26 | Dec 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $650 → $770 | $780.28 | -1.32% | 2 | Nov 24, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $18.31 | +336.92% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $3.69 | +143.90% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $30.25 | -53.72% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.79 | +570.39% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $21.63 | +154.28% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Perform | $55 | $74.16 | -25.84% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $4.84 | +209.92% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $77.82 | -35.75% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $7.33 | +104.64% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $37.95 | -55.20% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $72.89 | -3.96% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $16.99 | +194.29% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $9.79 | +206.44% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $18.44 | +198.26% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.36 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $49.37 | +224.08% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $55.57 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $223.26 | +7.50% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $27.05 | +66.36% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.57 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $27.67 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $1,044.67 | -15.28% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.24 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $27.49 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.78 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.52 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.99 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.12 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.75 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.70 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.75 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.20 | +1,931.25% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.72 | +83.82% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $14.89 | +235.80% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $26.88 | +86.01% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.48 | +101.61% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.56 | +1,515.36% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $0.66 | +255,294,907.56% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $203.22 | +26.96% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.28 | +3,806.25% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.22 | +1,539.34% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $8.04 | +459.70% | 1 | Jun 22, 2017 |
Teva Pharmaceutical Industries
Jan 29, 2026
Maintains: Sector Outperform
Price Target: $35 → $40
Current: $34.47
Upside: +16.04%
Johnson & Johnson
Jan 22, 2026
Maintains: Sector Outperform
Price Target: $230 → $265
Current: $238.64
Upside: +11.05%
Bristol-Myers Squibb Company
Jan 9, 2026
Maintains: Sector Perform
Price Target: $53 → $60
Current: $60.77
Upside: -1.27%
Merck & Co.
Dec 4, 2025
Maintains: Sector Outperform
Price Target: $105 → $120
Current: $117.65
Upside: +2.00%
Regeneron Pharmaceuticals
Nov 24, 2025
Maintains: Sector Perform
Price Target: $650 → $770
Current: $780.28
Upside: -1.32%
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $18.31
Upside: +336.92%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $3.69
Upside: +143.90%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $30.25
Upside: -53.72%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.79
Upside: +570.39%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $21.63
Upside: +154.28%
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $74.16
Upside: -25.84%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $4.84
Upside: +209.92%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $77.82
Upside: -35.75%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $7.33
Upside: +104.64%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $37.95
Upside: -55.20%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $72.89
Upside: -3.96%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $16.99
Upside: +194.29%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $9.79
Upside: +206.44%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $18.44
Upside: +198.26%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.36
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $49.37
Upside: +224.08%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $55.57
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $223.26
Upside: +7.50%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $27.05
Upside: +66.36%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.57
Upside: -
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $27.67
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $1,044.67
Upside: -15.28%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.24
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $27.49
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.78
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.52
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.99
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.12
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.75
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.70
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.75
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.20
Upside: +1,931.25%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.72
Upside: +83.82%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $14.89
Upside: +235.80%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $26.88
Upside: +86.01%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $2.48
Upside: +101.61%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.56
Upside: +1,515.36%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $0.66
Upside: +255,294,907.56%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $203.22
Upside: +26.96%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.28
Upside: +3,806.25%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.22
Upside: +1,539.34%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $8.04
Upside: +459.70%